Table 1.
Demographic and Other Baseline Characteristics of Study Participants
| Characteristics | Observed in >1 stage and eligibility stage <5 (N = 199), n (%) or median (IQR) | Observed in >1 stage and eligibility stage 5+ (N = 161), n (%) or median (IQR) | Observed in single stage (N = 35), n (%) or median (IQR) |
|---|---|---|---|
| Eligibility year | 2005 (1999–2008) | 1999 (1996–2001) | 2004 (1997–2007) |
| Days from estimated date of “HIV infection” to screeninga | 21 (14–34) | 79 (48–104) | 52 (24–71) |
| Age, years | 33 (27–40) | 32 (28–37) | 31 (24–40) |
| Male | 194 (97) | 159 (99) | 31 (89) |
| Raceb | |||
| White | 158 (80) | 143 (89) | 27 (77) |
| Hispanic | 17 (9) | 10 (6) | 5 (14) |
| African American | 14 (7) | 1 (1) | 0 (0) |
| Other | 9 (5) | 7 (4) | 3 (9) |
| Education, yearsc | 16 (13–16) | 15 (13–16) | 15 (13–16) |
| HIV risk group | |||
| MSM | 185 (93) | 145 (90) | 30 (86) |
| MSM/IDU | 7 (4) | 8 (5) | 0 (0) |
| IDU | 1 (1) | 1 (1) | 0 (0) |
| Heterosexual | 6 (3) | 4 (2) | 4 (11) |
| Other/unknown | 0 (0) | 3 (2) | 1 (3) |
| Symptoms at seroconversion | |||
| Yes | 183 (92) | 123 (76) | 30 (86) |
| No | 15 (8) | 38 (24) | 5 (14) |
| Unknown | 1 (1) | 0 (0) | 0 (0) |
| Referral | |||
| PCP/ED/ambulatory | 88 (44) | 46 (29) | 13 (37) |
| Health department/STD clinic | 76 (38) | 47 (29) | 6 (17) |
| AIDS clinic | 10 (5) | 8 (5) | 0 (0) |
| Other research study | 14 (7) | 41 (25) | 8 (23) |
| Self/friend/internet | 5 (3) | 6 (4) | 2 (6) |
| Partner/UWPIC enrollee | 3 (2) | 2 (1) | 5 (14) |
| Other | 3 (2) | 11 (7) | 1 (3) |
| Fiebig stage at eligibility | |||
| I | 10 (5) | — | — |
| I/II | 104 (52) | — | — |
| II | 13 (7) | — | — |
| III | 10 (5) | — | — |
| IV | 60 (30) | — | — |
| V | — | 50 (31) | 15 (43) |
| V/VI | — | 106 (66) | 3 (9) |
| VI | — | 0 (0) | 9 (26) |
| Missing/unavailable | 2 (1) | 5 (3) | 8 (23) |
| Fiebig stage at screening | |||
| I | 10 (5) | — | — |
| I/II | 3 (2) | — | — |
| II | 15 (8) | — | — |
| III | 7 (4) | — | — |
| IV | 30 (15) | — | — |
| V | 97 (49) | 52 (32) | 19 (54) |
| V/VI | 4 (2) | 5 (3) | 4 (11) |
| VI | 33 (17) | 104 (65) | 12 (34) |
| No antiretroviral therapy | 43 (22) | 43 (27) | 11 (31) |
| Non-HAART antiretroviral therapy | 4 (2) | 7 (4) | 0 |
| First HAART regimen | |||
| PI based | 80 (53) | 48 (43) | 8 (33) |
| NNRTI based | 33 (22) | 48 (43) | 7 (29) |
| Integrase inhibitor based | 29 (19) | 4 (4) | 5 (21) |
| NNRTI/PI based | 9 (6) | 10 (9) | 2 (8) |
| Entry inhibitor based | 0 (0) | 0 (0) | 1 (4) |
| 3TC/AZT/ABC | 0 (0) | 1 (1) | 1 (4) |
| HAART of unknown type | 1 (1) | 0 (0) | 0 (0) |
| Days from estimated date of infection to HAARTd | 42 (21–211) | 118 (79–721) | 74 (40–193) |
| First available on or after screening visit | |||
| CD4 count (cells/mm3)—calculatede | 515 (400–693) | 601 (469–792) | 643 (371–735) |
| HIV RNA (viral load), log10 copies/mL | 5.38 (4.57–6.08) | 4.39 (3.70–4.90) | 4.52 (3.52–5.23) |
n = 2 in eligibility <F5 and n = 3 in eligibility ≥F5 could not have an estimated date of “HIV infection” established with precision and are excluded here.
n = 1 in eligibility <F5 had missing race.
n = 4 in eligibility <F5, n = 6 in eligibility ≥F5, and n = 2 in only one stage missing years education.
n = 1 in eligibility ≥F5 could not have an estimated date of HIV infection established with precision and is excluded here.
n = 1 in eligibility <F5 and 1 in eligibility ≥F5 missing CD4 count.
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; ED, emergency department; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PCP, primary care provider; PI, protease inhibitor; UWPIC, University of Washington Primary Infection Clinic.